# Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

> **NCT05087030** · PHASE3 · COMPLETED · sponsor: **Gedeon Richter Plc.** · enrollment: 473 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** RGB-14-P
- **DRUG:** Prolia®

## Key facts

- **NCT ID:** NCT05087030
- **Lead sponsor:** Gedeon Richter Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-21
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-11-15
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05087030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05087030, "Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05087030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*